Sudden Vision Loss With Submacular Hemorrhage in a Patient Taking Apixaban
A 74-year-old man presents with 5 days of metamorphopsia in the right eye followed by a sudden dense central scotoma. Best-corrected acuity is 20/200 right and 20/30 left. In the right eye a thick submacular hemorrhage, about 4 disc diameters and more than 1 mm thick, involves the fovea and extends superiorly; there is no vitreous hemorrhage. The left eye shows drusen only. OCT confirms subretinal hyperreflective material and an elevated fovea. He takes apixaban 5 mg twice daily for atrial fibrillation, last dose this morning; blood pressure is 158/88 mmHg and eGFR 52 mL/min/1.73 m². He has never had anti-VEGF treatment. Cardiology has not been contacted, and the nearest vitreoretinal service is 90 minutes away. The patient asks whether the apixaban should be stopped and whether surgery would restore his sight.
1. Outline your immediate management, including the roles of intravitreal anti-VEGF alone, pneumatic displacement with intravitreal tPA, and observation. Explain how you would manage the apixaban.
Read the worked answer
Assessment. This is a thick (more than 1 mm), fovea-involving submacular hemorrhage from neovascular AMD, about 5 days old. The clot physically separates photoreceptors from the RPE and releases iron and fibrin, so the duration of foveal exposure is the main modifiable factor.
Options and reasoning.
- Intravitreal anti-VEGF alone is standard for the underlying CNV, but drug diffusion through a dense clot is poor. It is reasonable if gas or tPA is unavailable or the patient declines.
- Intravitreal tPA (25–50 µg in 0.1 mL, off-label) lyses the clot, and a gas bubble (C3F8 or SF6) displaces blood away from the fovea. Combine this with an anti-VEGF agent. Positioning is usually face-down or upright for 1–3 days, depending on the bubble and hemorrhage location. Evidence comes from case series, so consent must mention off-label status and incomplete recovery.
- Vitrectomy with subretinal tPA is reserved for massive clots, failure of displacement, or older hemorrhage, usually within 2–3 weeks.
Apixaban. Do not stop it for an intravitreal injection. A 30-gauge needle carries a very low bleeding risk, and systemic thrombolysis is not being given, so reversal is not routinely required. Stopping apixaban in atrial fibrillation risks stroke. Contact cardiology but do not delay treatment. Control blood pressure before injection; if it remains above 180/110 mmHg, treat first. Avoid adding aspirin or NSAIDs.
2. What prognostic factors and counseling points would you discuss with him about visual recovery and follow-up?
Read the worked answer
Prognostic factors. Duration of foveal detachment is the strongest: recovery is better within 7 days and progressively worse after 2–3 weeks. Size and thickness also matter; a hemorrhage larger than 3–4 disc diameters or thicker than 1 mm, with foveal involvement, predicts poorer acuity. Age, baseline acuity, and underlying CNV activity also count. Even successful displacement often yields 1–3 lines rather than full recovery, and metamorphopsia may persist.
Counseling. Explain that treatment aims to limit photoreceptor damage, not guarantee 20/20. Anti-VEGF will be needed long term with treat-and-extend or monthly monitoring; recurrence and fellow-eye conversion are possible, so home Amsler testing and regular review are important. He should continue apixaban under cardiology, keep blood pressure controlled, and not add aspirin unless prescribed. If surgery is chosen, discuss the small risks of endophthalmitis, retinal detachment, vitreous hemorrhage, and cataract. Document that tPA and gas are off-label. Arrange review within 1 week and OCT monthly initially.